11 Facts About Ranbaxy Laboratories

Ranbaxy Laboratories Limited was an Indian multinational pharmaceutical company that was incorporated in India in 1961 and remained an entity until 2014.

Ranbaxy Laboratories was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for Japanese company Shionogi.

In June 2008, Ranbaxy Laboratories settled the patent dispute with Pfizer, allowing them to sell atorvastatin calcium, the generic version of Lipitor and atorvastatin calcium-amlodipine besylate, the generic version of Pfizer's Caduet, in the US, starting on 30 November 2011.

On 1 December 2011, Ranbaxy Laboratories got approval from the FDA to launch the generic version of Lipitor in the United States after the drug's patent expired.

The addition of Ranbaxy Laboratories extended Daiichi-Sankyo's operations, with the combined company worth about US$30 billion.

Related searches

In 2012,2013, and 2014 Brand Trust Reports, Ranbaxy Laboratories was ranked 161st, 225th, and 184th respectively among India's most trusted brands.

Ranbaxy Laboratories then accused Thakur of visiting pornographic sites using his office computer, forcing him to resign in 2005.

On 9 November 2012, Ranbaxy Laboratories halted production and recalled 41 lots of atorvastatin due to glass particles being found in some bottles.

In May 2013, Ranbaxy Laboratories pleaded guilty and paid $500 million in fines, for felony charges relating to the manufacture and distribution of certain adulterated drugs made at two of Ranbaxy Laboratories's manufacturing facilities in India, and misrepresenting clinical generic drug data.

Ranbaxy Laboratories pleaded guilty to three felony FDCA counts, and four felony counts of knowingly making materially false statements to the FDA.

Ranbaxy Laboratories was prohibited from manufacturing FDA-regulated drugs at the Mohali facility until it complied with United States drug manufacturing requirements.